Lexeo Therapeutics (LXEO) & Its Peers Head-To-Head Survey

Lexeo Therapeutics (NASDAQ:LXEOGet Free Report) is one of 287 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Lexeo Therapeutics to related businesses based on the strength of its profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Lexeo Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexeo Therapeutics 0 0 6 0 3.00
Lexeo Therapeutics Competitors 1458 4590 12092 211 2.60

Lexeo Therapeutics currently has a consensus target price of $20.80, suggesting a potential upside of 38.67%. As a group, “Biological products, except diagnostic” companies have a potential upside of 64.81%. Given Lexeo Therapeutics’ rivals higher probable upside, analysts clearly believe Lexeo Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Lexeo Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lexeo Therapeutics N/A -155.79% -51.08%
Lexeo Therapeutics Competitors -4,862.30% -216.67% -46.34%

Valuation and Earnings

This table compares Lexeo Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lexeo Therapeutics $650,000.00 -$66.39 million -0.67
Lexeo Therapeutics Competitors $556.11 million -$37.27 million -23.89

Lexeo Therapeutics’ rivals have higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 50.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.